The IBD Restore Study

Currently Recruiting

26 Aug 2026

Up to $7,850

Brisbane, Australia

The study drug is a new medicine being developed to potentially treat people living with moderate to severe inflammatory bowel disease (IBD). 

IBD is a long-term condition that causes swelling and irritation in the digestive system. The two main types are Crohn’s disease and ulcerative colitis. People with IBD often experience flare-ups, where symptoms get worse for a while and then improve. 

This new medication is designed to calm down the overactive immune response in the gut by targeting several of the processes that lead to inflammation. By doing this, the treatment may help break the ongoing cycle of flare-ups and discomfort. 

By taking part, you’re helping researchers create better treatments that are easier to use and designed just for patients like you. Your involvement could make a real difference for thousands of people worldwide. It’s a powerful way to support medical progress and leave a positive impact on many lives. 

Apply now Speak with us 1800 243 733

Join our clinical trial

This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. 

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions. 

Join our clinical trial image

Why participate?

  • Contribute to Research that supports communities across the globe. 
  • Help Make Treatments More Inclusive and Effective 
  • Be the Reason Better Treatments Move Forward 

Study schedule

 

Intake 1 In-clinic stay:

26 August 2026 – 31 August 2026

 Follow-up visits:

3 September 2026 – 24 November 2026
Approx. 6 visits during this period

Study dates are subject to change. Our team will confirm details with you during the screening process.

Trial details

Study medication

Administered via an intravenous (IV) infusion or subcutaneous injection depending on your cohort

Ethics

An independent ethics committee has approved this clinical trial. 

  

Additional eligibility

  • Weigh more than 50kg 
  • Non-smokers or smoking no more than 5 cigarettes per week, no tobacco or nicotine use 24 hours prior to admission, 
  • Prescription medications must be complete 14 days prior to admission (as discussed with our medical team) 
  • No serious medical conditions 
  • Not pregnant or breastfeeding 
  • Willing to follow contraception guidelines (if applicable) 
  • Able to attend all study visits and follow instructions

Study duration

5-night in-clinic stay and 6 follow-up visits

Ethics

An independent ethics committee has approved this clinical trial.

Are you a match?

Age

18 - 45 years old

Remuneration

Up to $7,850 *with screening reimbursement.
Full details outlined in consent form.

Gender

Male, Female, Female (Post-menopausal) or Female of non-childbearing potential

BMI

BMI 18 - 32 kg/m2

Commitment

5 nights, 6 clinic visits

Register your interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg






















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information


Consent to Information Use and Future Contact